KIF4B: A Potential Drug Target for Various Diseases (G285643)

Target Name: KIF4B

NCBI ID: G285643

KIF4B

KIF4B: A Potential Drug Target for Various Diseases

KIF4B (KIF4B_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, lungs, and kidneys. It is a key regulator of the extracellular matrix (ECM), which is a complex network of tissue-associated molecules that provides structural and mechanical support for various tissues and organs. KIF4B is also involved in several cellular processes that are important for normal development, wound healing, and tissue repair.

Recent studies have identified KIF4B as a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug may have significant implications for human health.

One of the key reasons for the interest in KIF4B as a drug target is its role in several diseases that are a significant public health concern. For example, KIF4B is frequently overexpressed in various types of cancer, including breast, lung, and ovarian cancer. This increase in expression of KIF4B has been shown to contribute to the development and progression of these diseases.

In addition to its role in cancer, KIF4B has also been associated with several neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the symptoms associated with these diseases.

KIF4B's role in wound healing and tissue repair is also of interest as a potential drug target. Its ability to regulate the ECM has been shown to play a key role in the formation of new tissues during wound healing and tissue repair. This may make KIF4B a potential target for the treatment of wounds that are difficult to heal, such as diabetic foot ulcers or radiation wounds.

Another potential application of KIF4B as a drug target is its role in the regulation of cellular processes that are important for normal development and aging. The ECM provides a framework for the growth, differentiation, and repair of tissues, and KIF4B's role in this process has been shown to play a key role in the regulation of cell-cell adhesion, migration, and angiogenesis.

In conclusion, KIF4B is a protein that has significant implications as a drug target. Its unique structure and function make it an attractive target for the treatment of a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of KIF4B in these diseases and to develop effective treatments.

Protein Name: Kinesin Family Member 4B

Functions: Iron-sulfur (Fe-S) cluster binding motor protein that has a role in chromosome segregation during mitosis (By similarity). Translocates PRC1 to the plus ends of interdigitating spindle microtubules during the metaphase to anaphase transition, an essential step for the formation of an organized central spindle midzone and midbody and for successful cytokinesis (By similarity). May play a role in mitotic chromosomal positioning and bipolar spindle stabilization (By similarity)

The "KIF4B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF4B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets